Pathfinder Cell Therapy, Inc.
PFND · OTC
12/31/2014 | 12/31/2013 | 12/31/2012 | 12/31/2011 | |
|---|---|---|---|---|
| Revenue | $0 | $54 | $114 | $73 |
| % Growth | -100% | -52.6% | 56.2% | – |
| Cost of Goods Sold | $0 | $37 | $50 | $26 |
| Gross Profit | $0 | $17 | $64 | $47 |
| % Margin | – | 31.5% | 56.1% | 64.4% |
| R&D Expenses | $262 | $672 | $1,328 | $1,676 |
| G&A Expenses | $850 | $921 | $771 | $1,959 |
| SG&A Expenses | $857 | $944 | $796 | $1,989 |
| Sales & Mktg Exp. | $7 | $23 | $25 | $30 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,119 | $1,616 | $2,124 | $3,665 |
| Operating Income | -$1,119 | -$1,599 | -$2,060 | $3,926 |
| % Margin | – | -2,961.1% | -1,807% | 5,378.1% |
| Other Income/Exp. Net | -$275 | -$106 | -$96 | -$7,652 |
| Pre-Tax Income | -$1,394 | -$1,705 | -$2,156 | -$11,270 |
| Tax Expense | $0 | $106 | $96 | $7,652 |
| Net Income | -$1,669 | -$1,811 | -$2,252 | -$18,922 |
| % Margin | – | -3,353.7% | -1,975.4% | -25,920.5% |
| EPS | -0.003 | -0.003 | -0.003 | -0.036 |
| % Growth | 7.4% | 20.6% | 90.6% | – |
| EPS Diluted | -0.003 | -0.003 | -0.003 | -0.036 |
| Weighted Avg Shares Out | 667,161 | 667,161 | 667,162 | 526,105 |
| Weighted Avg Shares Out Dil | 667,161 | 667,161 | 667,162 | 526,105 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $195 | $96 | $108 |
| Depreciation & Amortization | $3 | -$78 | $20 | $19 |
| EBITDA | -$1,116 | -$1,588 | -$2,040 | -$3,599 |
| % Margin | – | -2,940.7% | -1,789.5% | -4,930.1% |